Your browser is no longer supported. Please, upgrade your browser.
Ironwood Pharmaceuticals, Inc.
Index- P/E14.68 EPS (ttm)0.89 Insider Own2.30% Shs Outstand160.97M Perf Week3.34%
Market Cap2.12B Forward P/E11.01 EPS next Y1.18 Insider Trans149.81% Shs Float159.78M Perf Month3.26%
Income142.80M PEG- EPS next Q0.22 Inst Own- Short Float12.48% Perf Quarter20.17%
Sales398.40M P/S5.31 EPS this Y74.90% Inst Trans-0.03% Short Ratio10.22 Perf Half Y26.61%
Book/sh0.68 P/B19.10 EPS next Y11.01% ROA27.30% Target Price12.67 Perf Year31.28%
Cash/sh2.69 P/C4.83 EPS next 5Y- ROE402.50% 52W Range8.63 - 13.34 Perf YTD14.05%
Dividend- P/FCF- EPS past 5Y21.60% ROI28.50% 52W High-1.88% Beta1.37
Dividend %- Quick Ratio- Sales past 5Y21.10% Gross Margin99.80% 52W Low51.69% ATR0.40
Employees232 Current Ratio22.80 Sales Q/Q11.10% Oper. Margin43.90% RSI (14)61.58 Volatility3.25% 3.10%
OptionableYes Debt/Eq0.00 EPS Q/Q1093.60% Profit Margin35.80% Rel Volume0.78 Prev Close12.99
ShortableYes LT Debt/Eq3.96 EarningsMay 06 BMO Payout0.00% Avg Volume1.95M Price13.09
Recom2.40 SMA203.22% SMA507.72% SMA20017.57% Volume1,277,569 Change0.78%
Sep-30-20Downgrade Wells Fargo Overweight → Equal Weight $14 → $9
Jun-17-20Initiated Northland Capital Outperform $14
Jul-10-19Resumed Credit Suisse Neutral
Mar-27-19Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-25-19Upgrade H.C. Wainwright Sell → Neutral $14
Jan-24-19Upgrade JP Morgan Underweight → Neutral
Nov-07-18Downgrade JP Morgan Neutral → Underweight
Nov-07-18Downgrade Credit Suisse Outperform → Neutral
Jul-23-18Initiated H.C. Wainwright Sell $12.50
May-09-18Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-05-18Downgrade BofA/Merrill Buy → Underperform
Dec-06-17Downgrade Mizuho Buy → Neutral $16
Jul-21-17Downgrade JP Morgan Overweight → Neutral
May-03-17Initiated Wells Fargo Outperform
Apr-07-17Reiterated Mizuho Buy $21 → $22
Feb-22-17Reiterated Barclays Equal Weight $13 → $16
Nov-04-16Reiterated Mizuho Buy $19 → $20
Oct-24-16Reiterated Wedbush Neutral $10 → $13
Oct-10-16Reiterated Mizuho Buy $24 → $19
Sep-27-16Reiterated WallachBeth Hold $15 → $17
Jul-22-21 04:01PM  
Jul-21-21 03:25AM  
Jul-12-21 03:39PM  
Jun-16-21 07:45AM  
Jun-15-21 03:04PM  
Jun-07-21 04:01PM  
May-26-21 04:01PM  
May-24-21 08:00AM  
May-17-21 08:30AM  
May-12-21 10:03AM  
May-10-21 06:16AM  
May-07-21 10:47AM  
May-06-21 02:01PM  
May-05-21 11:54AM  
May-03-21 12:02PM  
Apr-30-21 08:03AM  
Apr-29-21 05:04PM  
Apr-22-21 04:01PM  
Apr-20-21 10:13AM  
Apr-15-21 04:46AM  
Mar-19-21 11:30AM  
Mar-01-21 06:40AM  
Feb-27-21 06:15AM  
Feb-19-21 04:01PM  
Feb-17-21 12:00PM  
Feb-10-21 12:31PM  
Feb-09-21 08:09AM  
Feb-08-21 04:01PM  
Feb-03-21 04:01PM  
Jan-05-21 07:30AM  
Dec-05-20 11:32AM  
Dec-04-20 08:44AM  
Dec-03-20 08:30AM  
Nov-30-20 01:39PM  
Nov-27-20 12:20PM  
Nov-07-20 12:31AM  
Nov-06-20 04:01PM  
Nov-05-20 07:05PM  
Oct-29-20 12:35PM  
Oct-22-20 04:01PM  
Sep-30-20 11:08AM  
Sep-29-20 08:55AM  
Sep-27-20 07:33AM  
Sep-14-20 10:55PM  
Sep-05-20 11:31AM  
Sep-02-20 04:00PM  
Aug-26-20 12:20PM  
Aug-07-20 02:52PM  
Aug-06-20 10:45AM  
Jul-30-20 12:33PM  
Jul-23-20 04:05PM  
Jul-21-20 07:00AM  
Jul-12-20 07:40PM  
Jun-08-20 02:51AM  
Jun-05-20 11:31AM  
Jun-03-20 09:56AM  
May-28-20 09:10AM  
May-27-20 08:51AM  
May-11-20 06:53AM  
May-07-20 10:00PM  
May-06-20 07:15PM  
Apr-29-20 12:34PM  
Apr-28-20 04:05PM  
Apr-16-20 04:05PM  
Apr-10-20 08:49AM  
Apr-07-20 03:32PM  
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Currie Mark GDirectorJun 14Sale11.5923,571273,188570,187Jun 16 04:10 PM
MCCOURT Thomas APresident and Interim CEOMay 24Sale12.251,71621,021566,499May 26 04:01 PM
Shetzline MichaelCMO, SVP & Head of Drug Devt.May 24Sale12.252,07725,443197,437May 26 04:05 PM
Rickard JasonSVP, Chief Operating OfficerMay 24Sale12.255166,321362,538May 26 04:03 PM
DENNER ALEXANDER JDirectorMar 10Buy10.5475,000790,50016,390,000Mar 10 07:06 PM
DENNER ALEXANDER JDirectorMar 08Buy10.30150,0001,545,00016,315,000Mar 10 07:06 PM
DENNER ALEXANDER JDirectorMar 05Buy10.01175,0001,751,75016,165,000Mar 05 07:19 PM
DENNER ALEXANDER JDirectorMar 04Buy10.00250,0002,500,00015,990,000Mar 05 07:19 PM
DENNER ALEXANDER JDirectorMar 03Buy10.02350,0003,507,00015,740,000Mar 05 07:19 PM
DENNER ALEXANDER JDirectorMar 02Buy9.56500,0004,780,00015,390,000Mar 02 08:18 PM
DENNER ALEXANDER JDirectorMar 01Buy9.60344,9003,311,04014,890,000Mar 02 08:18 PM
Owens Edward PDirectorFeb 26Buy8.903,00026,700218,954Mar 02 04:41 PM
DENNER ALEXANDER JDirectorFeb 26Buy9.20505,1004,646,92014,545,100Mar 02 08:18 PM
Shetzline MichaelCMO, SVP & Head of Drug Devt.Feb 26Sale9.114,43940,439160,859Mar 02 04:44 PM
Rickard JasonSVP, Chief Operating OfficerFeb 26Sale9.1113,651124,361306,682Mar 02 04:43 PM
MCCOURT Thomas APresidentFeb 26Sale9.1114,685133,780471,577Mar 02 04:40 PM
Mallon MarkChief Executive OfficerFeb 26Sale9.1130,675279,449470,605Mar 02 04:37 PM
Kilroy ConorSVP, GC & SecretaryFeb 26Sale9.116,98963,670122,336Mar 02 04:36 PM
Consylman GinaSVP, CFO & TreasurerFeb 26Sale9.1118,406167,679336,244Mar 02 04:34 PM
Owens Edward PDirectorFeb 25Buy9.115,00045,550215,954Feb 26 05:15 PM
Owens Edward PDirectorFeb 24Buy9.267,00064,820210,954Feb 26 05:15 PM
MCCOURT Thomas APresidentDec 14Option Exercise9.8999,988988,881421,720Dec 16 04:49 PM
MacDonald KellyChief Accounting OfficerDec 04Option Exercise9.125,63951,42898,680Dec 08 04:01 PM
MacDonald KellyChief Accounting OfficerDec 04Sale12.505,63970,48893,041Dec 08 04:01 PM
MacDonald KellyChief Accounting OfficerNov 11Option Exercise9.313,56133,15396,602Nov 13 04:02 PM
MacDonald KellyChief Accounting OfficerNov 11Sale11.753,56141,84293,041Nov 13 04:02 PM
Kilroy ConorSVP, GC & SecretaryNov 09Sale10.928369,129128,833Nov 10 04:09 PM
Consylman GinaSVP, CFO & TreasurerNov 09Sale10.921,41515,452269,699Nov 10 04:03 PM
Rickard JasonSVP, Chief Operating OfficerNov 09Sale10.923944,302235,382Nov 10 04:12 PM
MacDonald KellyChief Accounting OfficerNov 09Sale10.9292510,10193,041Nov 10 04:10 PM
MacDonald KellyChief Accounting OfficerNov 06Sale11.251,87221,06093,966Nov 10 04:10 PM
MacDonald KellyChief Accounting OfficerOct 08Sale10.5022,714238,49795,838Oct 13 04:03 PM
McHugh JulieDirectorSep 08Sale9.777,95077,672123,107Sep 09 06:26 PM
Rickard JasonSVP, Chief Operating OfficerAug 17Sale10.146896,986235,776Aug 19 04:05 PM
MacDonald KellyChief Accounting OfficerAug 17Sale10.145755,830118,552Aug 19 04:01 PM